Procter and Gamble is trying to get FDA approval for Intrinsa. Intrinsa is mildly effective at increasing female sexual desire:
"In clinical trials, women who used Intrinsa had an increase in the number of 'satisfying episodes' of sex to five a month, from three. But women who received the placebo also had an increase - to four a month, from three. The definition of satisfying sex was left to the women, who kept log books during the clinical trials."
"Procter & Gamble is initially seeking F.D.A. approval for Intrinsa as a treatment for women who have had their ovaries removed. It said that 17 to 30 percent of the 10 million women who have undergone such surgery have 'hypoactive sexual desire disorder,' meaning low sex drive that they find distressing."
If the FDA approves Intrinsa, doctors can prescribe it off-label for other populations and disorders. The market for Intrinsa could be as big as the market for Viagra:
"The shares of Procter & Gamble gained $1.18 yesterday, to close at $54.66"
Unfortunately, like any medication, Intrinsa does have side effects
"Possible risks include hirsutism, acne, liver dysfunction, lowering of the voice, adverse lipid changes, virilization of a female fetus, and, as androgens are aromatized to estrogens, potentially the risks of estrogen therapy."